Asset Impairment, Restructuring, and Other Special Charges

12 Months Ended

Dec. 31, 2023

Restructuring and Related Activities [Abstract]

Asset Impairment, Restructuring, And Other Special Charges

Asset Impairment, Restructuring, and Other Special Charges

The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below:

	2023		2022		2021
Asset impairment and other special charges	$	22.2	$	221.6	$	303.1
Severance	45.5		23.0		13.0
Total asset impairment, restructuring, and other special charges	$	67.7	$	244.6	$	316.1

Asset impairment, restructuring, and other special charges recognized during the year ended December 31, 2022 were primarily related to an intangible asset impairment for GBA1 Gene Therapy, acquired in the Prevail acquisition, as a result of changes in key assumptions used in the valuation due to delays in estimated launch timing.

During the year ended December 31, 2021, we recognized $128.0 million of intangible asset impairment as a result of the decision by Bayer AG to discontinue the development of a Phase I molecule related to a contract-based intangible asset from our acquisition of Loxo Oncology, Inc. Additionally, we recognized $108.1 million of intangible asset impairment from the sale of the rights to Qbrexza®, as well as acquisition and integration costs associated with the acquisition of Prevail.